Lindbrook Capital LLC boosted its stake in Danaher Co. (NYSE:DHR) by 3.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,043 shares of the conglomerate’s stock after buying an additional 66 shares during the period. Lindbrook Capital LLC’s holdings in Danaher were worth $460,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. James Hambro & Partners grew its position in Danaher by 150.3% in the first quarter. James Hambro & Partners now owns 3,454 shares of the conglomerate’s stock worth $778,000 after buying an additional 2,074 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Danaher by 9.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 495,631 shares of the conglomerate’s stock valued at $110,692,000 after purchasing an additional 44,632 shares during the last quarter. Cypress Wealth Services LLC boosted its position in shares of Danaher by 4.5% in the 1st quarter. Cypress Wealth Services LLC now owns 1,395 shares of the conglomerate’s stock valued at $314,000 after purchasing an additional 60 shares during the period. J.W. Cole Advisors Inc. increased its stake in Danaher by 14.9% in the 1st quarter. J.W. Cole Advisors Inc. now owns 2,184 shares of the conglomerate’s stock worth $492,000 after purchasing an additional 284 shares in the last quarter. Finally, Csenge Advisory Group increased its stake in Danaher by 80.9% in the 1st quarter. Csenge Advisory Group now owns 2,752 shares of the conglomerate’s stock worth $639,000 after purchasing an additional 1,231 shares in the last quarter. Hedge funds and other institutional investors own 78.00% of the company’s stock.

DHR stock opened at $254.67 on Tuesday. The company has a quick ratio of 1.68, a current ratio of 2.08 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $181.65 billion, a price-to-earnings ratio of 51.55, a P/E/G ratio of 1.92 and a beta of 0.72. Danaher Co. has a 12 month low of $155.61 and a 12 month high of $260.37. The firm has a 50 day moving average of $234.48 and a two-hundred day moving average of $230.73.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, April 21st. The conglomerate reported $2.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.85. The company had revenue of $6.87 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 18.05% and a return on equity of 12.94%. The company’s revenue for the quarter was up 58.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 earnings per share. On average, research analysts expect that Danaher Co. will post 6.05 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, April 30th. Shareholders of record on Friday, March 26th were given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.33%. This is an increase from Danaher’s previous quarterly dividend of $0.18. The ex-dividend date was Thursday, March 25th. Danaher’s payout ratio is currently 19.00%.

A number of research firms have recently issued reports on DHR. Zacks Investment Research lowered shares of Danaher from a “hold” rating to a “sell” rating and set a $241.00 price target on the stock. in a report on Friday, April 9th. Citigroup boosted their price target on shares of Danaher from $275.00 to $315.00 in a report on Friday, April 23rd. Robert W. Baird boosted their price target on shares of Danaher from $249.00 to $270.00 and gave the company an “outperform” rating in a report on Friday, April 23rd. Jefferies Financial Group boosted their price target on shares of Danaher from $270.00 to $290.00 and gave the company a “buy” rating in a report on Friday, April 23rd. Finally, Wells Fargo & Company boosted their price target on shares of Danaher from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, April 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $265.63.

In related news, SVP Angela S. Lalor sold 6,437 shares of the company’s stock in a transaction on Friday, February 12th. The shares were sold at an average price of $244.70, for a total transaction of $1,575,133.90. Following the completion of the sale, the senior vice president now directly owns 25,148 shares of the company’s stock, valued at approximately $6,153,715.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joakim Weidemanis sold 17,169 shares of the company’s stock in a transaction on Tuesday, April 27th. The stock was sold at an average price of $258.76, for a total transaction of $4,442,650.44. Following the sale, the executive vice president now directly owns 84,420 shares of the company’s stock, valued at $21,844,519.20. The disclosure for this sale can be found here. Insiders sold 26,698 shares of company stock valued at $6,808,687 over the last three months. Insiders own 11.70% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Further Reading: Stock Symbol

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.